Xiromed launches generic Prilosec

Xiromed, a division of Insud Pharmaceuticals, is offering omeprazole delayed-release capsules in a dosage strength of 20 mg.

The medication is the generic of AstraZeneca/P&G’s Prilosec.

“Xiromed is committed to providing cost effective generic products to our customers, and the launch of Omeprazole Delayed Release Capsules is the latest example of that commitment.  We continue to be focused on expanding our portfolio and offering new products in a variety of dosage forms,” said Xiromed CEO, Narasimhan Mani.

Prilosec is a proton pump inhibitor indicated for the treatment in adults of duodenal ulcer and gastric ulcer and the treatment in adults and children of gastroesophageal reflux disease and maintenance of healing of erosive esophagitis.

Prilosec delayed-release capsules and its generics had a market value of $104.5 million for the 12-month period ended January 2021, according to IQVIA.